Tadalafil
Product Images NDC 50436-0372

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50436-0372). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504360372)

This is a description of a medication called Tadalafil, with a strength of 20 mg and 6 tablets called Migby. It was produced by Inas Pharm Limited in India and its NDC is 50436-0372-2. The medication should be stored at room temperature and kept out of reach of children. The serial number is 3000001042 and the lot number is X000. The text also includes three different NDC codes and their associated drug and lot numbers.*

FDA Label Image

Figure (Tadalafil Figure1)

FDA Label Image

Figure (Tadalafil Figure2)

FDA Label Image

Figure (Tadalafil Figure3)

FDA Label Image

Figure (Tadalafil Figure4)

This is a description of the plasma tadalafil concentration in micrograms per liter (ug/L) over time at different doses of tadalafil. The graph shows four lines representing different dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg doses for five consecutive days. The x-axis shows time in hours, and the y-axis shows the plasma tadalafil concentration. There is a gradual increase in concentration after each dose, with the once-daily 5-mg dose following 5 consecutive days of administration showing the highest and most sustained concentration over time.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

The text provides a figure or graph showing the change in the International Prostate Symptom Score (IPSS) total score over time in weeks for individuals who used Tadalafil and Placebo. The graph shows that Tadalafil had a significant effect in reducing the IPSS total score compared to Placebo. The study lasted for 12 weeks.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

FDA Label Image

Figure 7 (Tadalafil Figure7)

FDA Label Image

Figure 8 (Tadalafil Figure8)

FDA Label Image

Chemical Structure (Tadalafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.